化学
过氧化物酶体增殖物激活受体
兴奋剂
部分激动剂
配体(生物化学)
过氧化物酶体
PPAR激动剂
立体化学
药品
受体
过氧化物酶体增殖物
组合化学
结合位点
药理学
生物化学
医学
作者
Roberta Montanari,Fulvio Saccoccia,Elena Scotti,Maurizio Crestani,Cristina Godio,Federica Gilardi,Fulvio Loiodice,Giuseppe Fracchiolla,Antonio Laghezza,Paolo Tortorella,Antonio Lavecchia,Ettore Novellino,Fernando Mazza,Massimiliano Aschi,Giorgio Pochetti
摘要
The peroxisome proliferator-activated receptors (PPARs) are ligand-dependent transcription factors regulating glucose and lipid metabolism. The search for new PPAR ligands with reduced adverse effects with respect to the marketed antidiabetic agents thiazolidinediones (TZDs) and the dual-agonists glitazars is highly desired. We report the crystal structure and activity of the two enantiomeric forms of a clofibric acid analogue, respectively complexed with the ligand-binding domain (LBD) of PPARgamma, and provide an explanation on a molecular basis for their different potency and efficacy against PPARgamma. The more potent S-enantiomer is a dual PPARalpha/PPARgamma agonist which presents a partial agonism profile against PPARgamma. Docking of the S-enantiomer in the PPARalpha-LBD has been performed to explain its different subtype pharmacological profile. The hypothesis that partial agonists show differential stabilization of helix 3, when compared to full agonists, is also discussed. Moreover, the structure of the complex with the S-enantiomer reveals a new region of the PPARgamma-LBD never sampled before by other ligands.
科研通智能强力驱动
Strongly Powered by AbleSci AI